Persistence of apremilast in moderate‐to‐severe psoriasis: a real‐world analysis of 14 147 apremilast‐ and methotrexate‐naive patients in the French National Health Insurance database

Real‐world data on the persistence of apremilast vs. methotrexate are inconclusive. To assess and compare the long‐term persistence of apremilast and methotrexate in a large cohort of patients with psoriasis. All adult patients with psoriasis registered in the French national health insurance database (‘Système National des Données de Santé’) between 2009 and 2017 were eligible for inclusion. The study population comprised apremilast‐ and...